Product
Ciltacabtagene Autoleucel
1 clinical trial
2 indications
Indication
Multiple MyelomaIndication
Smoldering Plasma Cell MyelomaClinical trial
CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering MyelomaStatus: Recruiting, Estimated PCD: 2026-01-15